| Completed | This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intr NCT07445282 | Sheikh Zayed Medical College | Phase 4 |
| Not Yet Recruiting | ZyVac-TCV Bangladesh Study NCT06757283 | International Centre for Diarrhoeal Disease Research, Bangladesh | Phase 3 |
| Completed | Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) NCT06104345 | Helsinki University Central Hospital | Phase 4 |
| Completed | Diagnosis and Staging of Typhoid Fever Using Surface-enhanced Raman Spectroscopy Liquid Biopsy NCT06546982 | University Hospital, Aachen | N/A |
| Completed | Vellore Typhoid Vaccine Impact Trial NCT05500482 | Christian Medical College, Vellore, India | Phase 4 |
| Completed | Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in NCT05613205 | GlaxoSmithKline | Phase 1 |
| Completed | WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study NCT04543877 | USDA, Western Human Nutrition Research Center | EARLY_Phase 1 |
| Completed | Evaluation Study of DPP® Typhoid Assay NCT05579821 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Effectiveness of a Typhoid Conjugate Vaccine in DRC NCT05119426 | International Vaccine Institute | Phase 4 |
| Unknown | Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana NCT04852185 | International Vaccine Institute | Phase 4 |
| Unknown | TyVECO: Surveillance Protocol NCT05562102 | International Vaccine Institute | — |
| Completed | The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial) NCT04349826 | Oxford University Clinical Research Unit, Vietnam | Phase 4 |
| Unknown | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC NCT04235361 | University of Stirling | — |
| Unknown | Commercial Typhoid Tests Validation NCT04673487 | Kenya Medical Research Institute | — |
| Completed | Commercial Typhoid Tests Validation Trial NCT04801602 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Non-inferiority and Safety Study of EuTCV Compared to Typbar-TCV in Healthy 6 Months-45 Years Aged Participant NCT04830371 | EuBiologics Co.,Ltd | Phase 2 / Phase 3 |
| Active Not Recruiting | Induction of Gut Permeability by an Oral Vaccine NCT04083950 | USDA, Western Human Nutrition Research Center | EARLY_Phase 1 |
| Completed | Comparison of Two Drugs Regimen in Treatment of Complicated Typhoid Fever in Children NCT04154722 | Ziauddin University | Phase 4 |
| Completed | Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy Adults NCT03956524 | EuBiologics Co.,Ltd | Phase 1 |
| Completed | Typhoid Conjugate Vaccine Introduction in Navi Mumbai, India NCT03554213 | Stanford University | — |
| Completed | Safety and Immunogenicity of Typhax, a Typhoid Vaccine NCT03926455 | Matrivax Research and Development Corporation | Phase 1 |
| Completed | Vaccines Against Salmonella Typhi NCT02324751 | University of Oxford | Phase 2 |
| Completed | Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers NCT02391909 | Bavarian Nordic | — |
| Completed | Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study NCT02192008 | University of Oxford | N/A |
| Unknown | Typhoid Fever: Combined vs. Single Antibiotic Therapy NCT02224040 | Sheba Medical Center | Phase 4 |
| Completed | Global Genomic and Proteomic Profiling of African Children With Typhoid Fever NCT02947295 | University of Nebraska | — |
| Completed | Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects NCT01608815 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Understanding Typhoid Disease After Vaccination NCT01405521 | University of Oxford | Phase 2 |
| Completed | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants NCT01437267 | Novartis | Phase 2 |
| Completed | Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults NCT01438996 | Novartis | Phase 2 |
| Completed | Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever NCT01421693 | Oxford University Clinical Research Unit, Vietnam | Phase 4 |
| Completed | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants NCT01229176 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years O NCT01193907 | Novartis | Phase 2 |
| Completed | Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) NCT01123941 | Novartis | Phase 1 |
| Completed | Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) NCT00498654 | Avant Immunotherapeutics | Phase 2 |
| Completed | Long Term Protection by and Persistence of Vi Antibodies Induced by Vi-rEPA Conjugate Vaccines in Vietnamese C NCT00386789 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | — |
| Completed | Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants NCT00342628 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 |
| Completed | CVD 909 Vi Prime Boost Study NCT00326443 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Salmonella Typhi Vi O-Acetyl Pectin-rEPA Conjugate Vaccine NCT00277147 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 1 |